---
title: Mirum Pharma CEO Christopher Peetz Has Sold $10.4M — MIRM Stock Up 4x From His Exercise Prices
type: news
slug: mirum-pharma-ceo-peetz-10-million-career-insider-sales
canonical_url: https://13finsight.com/news/mirum-pharma-ceo-peetz-10-million-career-insider-sales
published_at: 2026-03-01T18:18:28.733Z
updated_at: 2026-03-01T18:18:39.551Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 270
locale: en
source: 13F Insight
---

# Mirum Pharma CEO Christopher Peetz Has Sold $10.4M — MIRM Stock Up 4x From His Exercise Prices

> Mirum Pharmaceuticals CEO Christopher Peetz sold $10.4M across 81 transactions, exercising options as low as $2.94 and selling at $55-$103/share as MIRM stock surged on Livmarli success.

Christopher Peetz, CEO of Mirum Pharmaceuticals (MIRM), has sold $10.4 million across 81 insider transactions. His February 2026 sale of 9,108 shares at $103.30 marks the highest price in his selling history — a 35x return on options originally granted at $2.94/share. The Numbers MetricValue Career Sell Value$10.4M Career Buy Value$314K Total Transactions81 Last Transaction2026-02-02 Shares Remaining160,294 Recent Activity DateTypeSharesPriceEst. Value 2026-02-02Sell9,108$103.3035$941K 2025-11-18Exercise19,133N/A$0 2025-11-18Exercise19,133$19.2400$368K 2025-08-11Sell40,000$62.0000$2.5M Peetz's selling accelerated in 2025 as MIRM surged on Livmarli's commercial success: $2.2M at $55 in August, $2.5M at $62 in August, and $941K at $103 in February 2026. The exercise-and-sell pattern shows him converting deep-in-the-money options into cash as the stock price rises, a common pattern for biotech CEOs whose companies transition from clinical to commercial stage. What It Means The spread between Peetz's exercise prices ($2.94-$19.24) and selling prices ($55-$103) represents the value creation journey of a successful biotech: from pre-approval uncertainty to commercial-stage validation. His $10.4M in career sales came almost entirely in 2025-2026 as Livmarli's launch in cholestatic liver diseases drove MIRM from ~$30 to $100+. With 160,294 shares remaining (~$16.5M at current prices), Peetz's retained position exceeds his career sales — a positive alignment signal for MIRM investors. The CEO is monetizing some of his paper gains while maintaining a larger bet on the company's pipeline expansion beyond Livmarli. His $314K in career purchases shows he also bought stock at earlier, lower prices. What to Watch Whether Peetz continues selling as MIRM trades above $100 Livmarli prescription volume trends and payer coverage expansion Mirum's pipeline readouts beyond Livmarli for additional indications Other MIRM insiders' selling activity at these elevated levels

---

Source: 13F Insight — https://13finsight.com/news/mirum-pharma-ceo-peetz-10-million-career-insider-sales
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-01T18:18:39.551Z